8-K current report · filed Nov 12, 2026

Arbutus Biopharma Corp (ABUS) 8-K Current Report: November 12, 2026

Item 8.01Item EX-99.1ABUS overview

Short answer

Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Updated corporate presentation posted November 12, 2026.

Arbutus Biopharma Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Updated corporate presentation posted November 12, 2026
  • Investor relevance depends on substantive pipeline, clinical, financing or strategic updates in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Q4 2026 corporate presentation highlights imdusiran as the lead cHBV asset, with potential Phase 2b development plans under evaluation
  • Cash and equivalents of $104.6M as of October 31, 2026, supporting near-term clinical development
  • Phase 2a data: 46% of 105 patients achieved functional cure or discontinued NA therapy
  • Long-term follow-up: 16 of 18 patients who stopped NA therapy remained off treatment through up to 146+ weeks
  • Key risks remain clinical validation, regulatory approval, patent litigation, and cash-resource sufficiency

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Arbutus Biopharma Corp 8-K filings

Get the next ABUS 8-K as it lands

Follow ABUS for push alerts, or ask the research agent what this filing means.